stockrow
Saturday 7 November 2026
Export PRLD’s income statement to Excel — free account
Prelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024.
- Revenue
- +42.6%
- EPS
- +65.9%
- Free cash flow
- +40.3%
Quarter to June 2026, against a year earlier
3.60
0.04
+1.12%
Follow PRLD
Alert me
Prelude Therapeutics Incorporated (PRLD) P/E ratio
Prelude Therapeutics Incorporated has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| AGEN Agenus Inc. compare | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)